HR Stock Analysis: Healthcare Realty Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 6.661m USD | 12M Return: 17.9% | US42226K1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 59.7M
Qual. Beats: 0
Rev. Trend: -99.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Healthcare Realty Trust Incorporated (NYSE: HR) is a healthcare-focused real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily situated around market-leading hospital campuses. The company grows its portfolio through both property acquisitions and development, and as of September 30, 2025, it held investments in 579 real estate properties across 28 states, totaling 33.6 million square feet, with an enterprise value of approximately $11.1 billion.
Headquartered in Nashville, Tennessee and incorporated in 1992, Healthcare Realty Trust is classified within the GICS Health Care REITs sub-industry and trades as a mid-cap stock with a market capitalization of approximately $6.94 billion. As a REIT, the company is generally required to distribute the majority of its taxable income to shareholders in the form of dividends, a structural feature that distinguishes it from conventional real estate operators. Its focus on outpatient medical facilities-rather than hospitals or skilled nursing-places it in a specialized segment of healthcare real estate that typically benefits from long-term tenant leases with health systems and physician groups.
- Outpatient care shift boosts medical office building demand
- Rising interest rates pressure cap rates and acquisition pace
- Same-store NOI growth driven by rent escalators and occupancy gains
| Net Income: -86.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.28 > 1.0 |
| NWC/Revenue: -13.52% < 20% (prev -11.10%; Δ -2.42% < -1%) |
| CFO/TA 0.05 > 3% & CFO 441.2m > Net Income -86.9m |
| Net Debt (4.62b) to EBITDA (678.4m): 6.81 < 3 |
| Current Ratio: 0.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (342.3m) vs 12m ago -2.10% < -2% |
| Gross Margin: 16.57% > 18% (prev -39.49%; Δ 56.06% > 0.5%) |
| Asset Turnover: 11.90% > 50% (prev 11.94%; Δ -0.03% > 0%) |
| Interest Coverage Ratio: 0.73 > 6 (EBIT TTM 132.7m / Interest Expense TTM 180.7m) |
| A: -0.02 (Total Current Assets 19.0m - Total Current Liabilities 173.8m) / Total Assets 9.00b |
| B: 0.01 (Retained Earnings 84.7m / Total Assets 9.00b) |
| C: 0.01 (EBIT TTM 132.7m / Avg Total Assets 9.62b) |
| D: 0.89 (Book Value of Equity 4.22b / Total Liabilities 4.73b) |
| Altman-Z'' = 0.95 = BB |
As of September 02, 2026, the stock is trading at USD 19.36 with a total of 3,738,265 shares traded. Over the past week, the price has changed by -0.15%, over one month by -4.58%, over three months by +0.61% and over the past year by +17.86%.
Current recommended Stop Loss: 18.50 (which is 4.4% or 2.8 ATR below the current price).
Healthcare Realty Trust has received a consensus analysts rating of 3.45. Therefore, it is recommended to hold HR.
- StrongBuy: 2
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.6 | 11.5% |
P/E Forward = 10.8342
P/S = 5.74
P/B = 1.5547
P/EG = 8.8222
Revenue TTM = 1.14b USD
EBIT TTM = 132.7m USD
EBITDA TTM = 678.4m USD
Long Term Debt = 3.89b USD (from longTermDebt, last quarter)
Short Term Debt = 5.53m USD (from shortTermDebt, last quarter)
Debt = 4.64b USD (from shortLongTermDebtTotal, last quarter) + Leases 235.6m
Net Debt = 4.62b USD (calculated: Debt 4.64b - CCE 19.0m)
Enterprise Value = 11.3b USD (6.66b + Debt 4.64b - CCE 19.0m)
Interest Coverage Ratio = 0.73 (Ebit TTM 132.7m / Interest Expense TTM 180.7m)
EV/FCF = 83.66x (Enterprise Value 11.3b / FCF TTM 134.8m)
FCF Yield = 1.20% (FCF TTM 134.8m / Enterprise Value 11.3b)
FCF Margin = 11.78% (FCF TTM 134.8m / Revenue TTM 1.14b)
Net Margin = -7.59% (Net Income TTM -86.9m / Revenue TTM 1.14b)
Gross Margin = 16.57% ((Revenue TTM 1.14b - Cost of Revenue TTM 955.2m) / Revenue TTM)
Gross Margin QoQ = 64.36% (prev 64.14%)
Tobins Q-Ratio = 1.25 (Enterprise Value 11.3b / Total Assets 9.00b)
Interest Expense / Debt = 3.90% (Interest Expense 180.7m / Debt 4.64b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 104.8m (EBIT 132.7m * (1 - 21.00%))
Current Ratio = 0.11 (Total Current Assets 19.0m / Total Current Liabilities 173.8m)
Debt / Equity = 1.10 (Debt 4.64b / totalStockholderEquity, last quarter 4.22b)
Debt / EBITDA = 6.81 (Net Debt 4.62b / EBITDA 678.4m)
Debt / FCF = 34.26 (Net Debt 4.62b / FCF TTM 134.8m)
Total Stockholder Equity = 4.49b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.90% (Net Income -86.9m / Total Assets 9.00b)
RoE = -1.94% (Net Income TTM -86.9m / Total Stockholder Equity 4.49b)
RoCE = 1.58% (EBIT 132.7m / Capital Employed (Equity 4.49b + L.T.Debt 3.89b))
RoIC = 1.19% (NOPAT 104.8m / Invested Capital 8.81b)
WACC = 4.92% (E(6.66b)/V(11.3b) * Re(6.20%) + D(4.64b)/V(11.3b) * Rd(3.90%) * (1-Tc(0.21)))
Discount Rate = 6.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.75 | Cagr: -4.48%
[DCF] Terminal Value 73.10% ; FCFF base≈153.8m ; Y1≈134.9m ; Y5≈109.0m
[DCF] Fair Price = N/A (negative equity: EV 1.75b - Net Debt 4.62b = -2.87b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.49 | # QB: 0
Revenue Correlation: -99.48 | Revenue CAGR: -6.29% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.00 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.10 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+86.1% | GrowthRev=-4.8%
EPS next Year (2027-12-31): EPS=0.02 | Chg30d=+150.00% | Revisions=+25% | GrowthEPS=+9.1% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +25% (up=1, down=0)